Cytotoxic and apoptotic effects of melatonin hormone on NB4 leukemic cells

authors:

avatar Mahdieh Mehrpouri , avatar Ramin Yousefpour , avatar Ava Safaroghli-Azar ORCID , avatar Davood Bashash ORCID , *

Koomesh: Vol.22, issue 3; 534-541
article type: issue_documents_importer
received: October 02, 2019
accepted: January 02, 2020

how to cite: Mehrpouri M, Yousefpour R, Safaroghli-Azar A, Bashash D. Cytotoxic and apoptotic effects of melatonin hormone on NB4 leukemic cells. koomesh. 2020;22(3):e153211. 

Abstract

Introduction: Given to the fact that the high toxicity and side effects of chemotherapeutic drugs have limited their clinical use, it is not surprising that novel therapeutic drugs with less toxicity and more efficacy have entered into the novel protocols. Relatively, Melatonin, a main product of pineal gland, not only plays a key role in the regulation of circadian rhythm, but also exerts anti-proliferative and apoptotic effects on a wide range of tumors. The aim of this study was to evaluate the anti-proliferative and apoptotic effects of melatonin in acute promyelocytic leukemia-derived cell line NB4. Materials and Methods: NB4 cells were exposed to the increasing concentrations of the melatonin drug (0.5, 1, and 2 mM). Subsequently, metabolic activity, induction of apoptosis, caspase-3 activity, ROS production and apoptosis-related target genes were investigated using MTT assay, Annexin-V/PI staining, caspase-3 activity kit, cellular ROS assay kit and RQ-PCR analysis, respectively. Results: Our data delineated that melatonin resulted in the reduction of metabolic activity of NB4 cells in a dose- and time-dependent manner (P

References

  • 1.

    Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114: 5126-5135.

  • 2.

    Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. The Lancet 2013; 381: 484-495.

  • 3.

    Rogaia D, Grignani F, Nicoletti I, Pelicci P. The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells. Leukemia 1995; 9: 1467-1472.

  • 4.

    Rowley J, Golomb H, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. The Lancet 1977; 309: 549-550.

  • 5.

    Wu J, Wong WW-L, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004; 64: 6461-6468.

  • 6.

    Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002; 99: 1909-1912.

  • 7.

    Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. The Oncologist 2001; 6: 1-2.

  • 8.

    Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.

  • 9.

    Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008; 7: 189-203.

  • 10.

    Bonnefont-Rousselot D, Collin F. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology 2010; 278: 55-67.

  • 11.

    Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Progress in brain research. Elsevier 2010; 127-151.

  • 12.

    Dauchy RT, Xiang S, Mao L, Brimer S, Wren MA, Yuan L, et al. Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res 2014; 74: 4099-4110.

  • 13.

    Sainz RM, Mayo JC, Tan Dx, Len J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. The Prostate 2005; 63: 29-43.

  • 14.

    Alonso-Gonzlez C, Menndez-Menndez J, Gonzlez-Gonzlez A, Gonzlez A, Cos S, Martnez-Campa C. Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF7 human breast cancer cells. Int J Oncol 2018; 52: 560-570.

  • 15.

    Song J, Ma S-J, Luo J-H, Zhang H, Wang R-X, Liu H et al. Melatonin induces the apoptosis and inhibits the proliferation of human gastric cancer cells via blockade of the AKT/MDM2 pathway. Oncology reports 2018; 39: 1975-83.

  • 16.

    Li T, Yang Z, Jiang S, Di W, Ma Z, Hu W, et al. Melatonin: does it have utility in the treatment of haematological neoplasms? Br J Pharmacol 2018; 175: 3251-3262.

  • 17.

    Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005; 115: 2665-2672.

  • 18.

    Lee SH, Lee EH, Lee SH, Lee YM, Kim HD, Kim YZ. Epigenetic role of histone 3 lysine methyltransferase and demethylase in regulating apoptosis predicting the recurrence of atypical meningioma. J Korean Med Sci 2015; 30: 1157-1166.

  • 19.

    Bonmati-Carrion MA, Arguelles-Prieto R, Martinez-Madrid MJ, Reiter R, Hardeland R, Rol MA, et al. Protecting the melatonin rhythm through circadian healthy light exposure. Int J Mol Sci 2014; 15: 23448-23500.

  • 20.

    Tanaka T, Yasui Y, Tanaka M, Tanaka T, Oyama T, Rahman KW. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009; 177: 128-136.

  • 21.

    Snchez-Barcel E, Mediavilla M, Tan D, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-2095.

  • 22.

    Lahti TA, Partonen T, Kyyrnen P, Kauppinen T, Pukkala E. Nighttime work predisposes to nonHodgkin lymphoma. Int J Cancer 2008; 123: 2148-2151.

  • 23.

    Yong M, Nasterlack M, Messerer P, Oberlinner C, Lang S. A retrospective cohort study of shift work and risk of cancer-specific mortality in German male chemical workers. Int Arch Occup Environ Health 2014; 87: 175-183.

  • 24.

    Rana S, Shahid A, Ullah H, Mahmood S. Lack of association of the NPAS2 gene Ala394Thr polymorphism (rs2305160: G> A) with risk of chronic lymphocytic leukemia. Asian Pac J Cancer Prev 2014; 15: 7169-7174.

  • 25.

    Parent M, El-Zein M, Rousseau MC, Pintos J, Siemiatycki J. Night work and the risk of cancer among men. Am J Epidemiol 2012; 176: 751-759.

  • 26.

    Nooshinfar E, Bashash D, Safaroghli-Azar A, Bayati S, Rezaei-Tavirani M, Ghaffari SH, et al. Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer. Biomed Pharmacother 2016; 83: 456-465.

  • 27.

    Krestinina O, Fadeev R, Lomovsky A, Baburina Y, Kobyakova M, Akatov V. Melatonin Can Strengthen the Effect of Retinoic Acid in HL-60 Cells. Int J Mol Sci 2018; 19: 2873.

  • 28.

    Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.

  • 29.

    Rubio S, Estvez F, Cabrera J, Reiter RJ, Loro J, Quintana J. Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL60 cells. J Pineal Res 2007; 42: 131-138.

  • 30.

    Bykavc M, zdemir , Buck S, Stout M, Ravindranath Y, Savaan S. Melatonin cytotoxicity in human leukemia cells: relation with its prooxidant effect. Fundam Clin Pharmacol 2006; 20: 73-79.